Glioblastoma Cells Do Not Affect Axitinib-Dependent Senescence of HUVECs in a Transwell Coculture Model
出版年份 2020 全文链接
标题
Glioblastoma Cells Do Not Affect Axitinib-Dependent Senescence of HUVECs in a Transwell Coculture Model
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 4, Pages 1490
出版商
MDPI AG
发表日期
2020-02-24
DOI
10.3390/ijms21041490
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Axitinib exposure triggers endothelial cells senescence through ROS accumulation and ATM activation
- (2019) Maria Patrizia Mongiardi et al. ONCOGENE
- Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms
- (2018) Federica Grillo et al. ENDOCRINE-RELATED CANCER
- A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot consortium trial (ADVL1315)
- (2018) James I. Geller et al. CANCER
- The dynamic nature of senescence in cancer
- (2018) Soyoung Lee et al. NATURE CELL BIOLOGY
- Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
- (2017) Audrey Bellesoeur et al. Drug Design Development and Therapy
- Mitochondrial Dysfunction Induces Senescence with a Distinct Secretory Phenotype
- (2016) Christopher D. Wiley et al. Cell Metabolism
- Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma
- (2016) J. Duerinck et al. JOURNAL OF NEURO-ONCOLOGY
- NOTCH1 mediates a switch between two distinct secretomes during senescence
- (2016) Matthew Hoare et al. NATURE CELL BIOLOGY
- Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner
- (2016) Maria Beatrice Morelli et al. Oncotarget
- A complex secretory program orchestrated by the inflammasome controls paracrine senescence
- (2013) Juan Carlos Acosta et al. NATURE CELL BIOLOGY
- Pathological neoangiogenesis depends on oxidative stress regulation by ATM
- (2012) Yuji Okuno et al. NATURE MEDICINE
- Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma
- (2011) J. Fruehauf et al. CLINICAL CANCER RESEARCH
- Four faces of cellular senescence
- (2011) Francis Rodier et al. JOURNAL OF CELL BIOLOGY
- Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
- (2011) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression
- (2010) Jean-Philippe Coppé et al. Annual Review of Pathology-Mechanisms of Disease
- The essence of senescence
- (2010) T. Kuilman et al. GENES & DEVELOPMENT
- Stress-Response Hormesis and Aging: “That which Does Not Kill Us Makes Us Stronger”
- (2008) David Gems et al. Cell Metabolism
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started